Canadian society of nephrology commentary on the 2012 kdigo clinical practice guideline for anemia in CKD

American Journal of Kidney Diseases

Volumn 62, Issue 5, 2013, Pages 860-873

  Moist, Louise M ^a   Troyanov, Stéphan ^b   White, Colin T ^c   Wazny, Lori D ^d   Wilson, Jo Anne ^e   McFarlane, Phil ^f   Harwood, Lori ^a   Sood, Manish M ^g   Soroka, Steven D ^e   Bass, Adam ^h   Manns, Braden J ^h  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d WINNIPEG REGIONAL HEALTH AUTHORITY   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

Author keywords

Anemia; Canadian Society of Nephrology (CSN); chronic kidney disease (CKD); clinical practice guideline; commentary; Kidney Disease: Improving Global Outcomes (KDIGO)

Indexed keywords

ANTIANEMIC AGENT; FERRIC GLUCONATE; FERRITIN; FERUMOXYTOL; HEMOGLOBIN; IRON; IRON DEXTRAN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ALLERGIC REACTION; ANEMIA; BLOOD TRANSFUSION; CANADA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG COST; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HEALTH CARE SYSTEM; HUMAN; INDIVIDUALIZATION; IRON THERAPY; KIDNEY DISEASE IMPROVING GLOBAL OUTCOMES; MALIGNANT NEOPLASTIC DISEASE; MEDICAL HISTORY; MEDICAL SOCIETY; NEPHROLOGY; PRACTICE GUIDELINE; PURE RED CELL ANEMIA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; TRANSFERRIN BLOOD LEVEL;

EID: 84886718491     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.08.001     Document Type: Article

References (62)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease Kidney Int Suppl 2 2012 279 335
2. M.C. Brouwers, M.E. Kho, G.P. Browman AGREE II: advancing guideline development, reporting and evaluation in health care CMAJ 182 2010 E839 E842
3. B.J. Manns, C.T. White, F. Madore Introduction to the Canadian Society of Nephrology clinical practice guidelines for the management of anemia associated with chronic kidney disease Kidney Int Suppl 2008 S1 S3
4. B.J. Manns, A. Hodsman, D.L. Zimmerman Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD) Am J Kidney Dis 55 2010 800 812
5. M. James, J. Bouchard, J. Ho Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury Am J Kidney Dis 61 2013 673 685
6. H. Pfaff, E. Driller, N. Ernstmann Standardization and individualization in care for the elderly: proactive behavior through individualized standardization Open Longevity Sci 4 2010 51 57
7. A. Levin, O. Djurdjev, C. Thompson Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD Am J Kidney Dis 46 2005 799 811
8. N.C. Boudville, O. Djurdjev, I.C. Macdougall Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality Clin J Am Soc Nephrol 4 2009 1176 1182
9. F. Madore, C.T. White, R.N. Foley Clinical practice guidelines for assessment and management of iron deficiency Kidney Int Suppl 2008 S7 S11
10. S. Stancu, A. Stanciu, A. Zugravu Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD Am J Kidney Dis 55 2010 639 647
11. K. Kalantar-Zadeh, B. Hoffken, H. Wunsch, H. Fink, M. Kleiner, F.C. Luft Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era Am J Kidney Dis 26 1995 292 299
12. N. Milman, T.E. Christensen, N.S. Pedersen, J. Visfeldt Serum ferritin and bone marrow iron in non-dialysis, peritoneal dialysis and hemodialysis patients with chronic renal failure Acta Med Scand 207 1980 201 205
13. A. Besarab, N. Amin, M. Ahsan Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients J Am Soc Nephrol 11 2000 530 538
14. M.V. DeVita, D. Frumkin, S. Mittal, A. Kamran, S. Fishbane, M.F. Michelis Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients Clin Nephrol 60 2003 335 340
15. D.W. Coyne, T. Kapoian, W. Suki Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study J Am Soc Nephrol 18 2007 975 984
16. B.M. Robinson, M. Larkina, Y. Li IV iron dosing and changes in serum TSAT, ferritin, and hemoglobin levels: implications of increasing IV iron dosing in the US [abstract] J Am Soc Nephrol 23 2012 21A
17. K. Kalantar-Zadeh, B. Hoffken, H. Wunsch, H. Fink, M. Kleiner, F.C. Luft Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era Am J Kidney Dis 26 1995 292 299
18. Dextron [product monograph] May 1996 Luitpold Pharmaceuticals, Inc Shirley, NY
19. Infufer [product monograph] July 2005 Sandoz Canada Inc Boucherville, Quebec
20. Venofer [product monograph] December 2006 Genpharm Inc Toronto, Ontario
21. Ferrlecit [product monograph] August 2012 Sanofi-Aventis Canada Inc Laval, Quebec
22. Feraheme [product monograph] September 2012 Takeda Canada Inc Oakville, Ontario
23. G.M. Chertow, P.D. Mason, O. Vaage-Nilsen, J. Ahlmen Update on adverse drug events associated with parenteral iron Nephrol Dial Transplant 21 2006 378 382
24. G.R. Bailie, W.H. Horl, J.J. Verhoef Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America Arzneimittelforschung 61 2011 267 275
25. G.R. Bailie, J.A. Clark, C.E. Lane, P.L. Lane Hypersensitivity reactions and deaths associated with intravenous iron preparations Nephrol Dial Transplant 20 2005 1443 1449
26. G.R. Bailie Comparison of rates of reported adverse events associated with i.v. iron products in the United States Am J Health Syst Pharm 69 2012 310 320
27. E. Coppol, J. Shelly, S. Cheng, Y. Kaakeh, B. Shepler A comparative look at the safety profiles of intravenous iron products used in the hemodialysis population (February) Ann Pharmacother 45 2011 241 247
28. A. Hayat Safety issues with intravenous iron products in the management of anemia in chronic kidney disease Clin Med Res 6 2008 93 102
29. M. Auerbach, T.K. Al Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease Kidney Int 73 2008 528 530
30. G. Anirban, H.S. Kohli, V. Jha, K.L. Gupta, V. Sakhuja The comparative safety of various intravenous iron preparations in chronic kidney disease patients Ren Fail 30 2008 629 638
31. M.H. Schwenk Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease Pharmacotherapy 30 2010 70 79
32. M. Auerbach, R.C. Kane Caution in making inferences from FDA's Adverse Event Reporting System Am J Health Syst Pharm 69 2012 922 923
33. M. Auerbach, H. Ballard Clinical use of intravenous iron: administration, efficacy, and safety Hematology Am Soc Hematol Educ Program 2010 2010 338 347
34. D.B. Van Wyck Labile iron: manifestations and clinical implications J Am Soc Nephrol 15 suppl 2 2004 S107 S111
35. G.R. Aronoff Safety of intravenous iron in clinical practice: implications for anemia management protocols J Am Soc Nephrol 15 suppl 2 2004 S99 S106
36. Canadian Institute for Health Information 2011 Annual Report - Treatment of End-Stage Organ Failure in Canada, 2000 to 2009 Candian Organ Replacement Register Annual Report 2011 CIHI Ottawa, Ontario
37. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
38. J. Bohlius, K. Schmidlin, C. Brillant Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials Lancet 373 2009 1532 1542
39. M. Tonelli, B. Hemmelgarn, T. Reiman Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis CMAJ 180 2009 E62 E71
40. J.D. Rizzo, M. Brouwers, P. Hurley American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer J Clin Oncol 28 2010 4996 5010
41. P.S. Parfrey, R.N. Foley, B.H. Wittreich, D.J. Sullivan, M.J. Zagari, D. Frei Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease J Am Soc Nephrol 16 2005 2180 2189
42. S.D. Solomon, H. Uno, E.F. Lewis Erythropoietic response and outcomes in kidney disease and type 2 diabetes N Engl J Med 363 2010 1146 1155
43. H. Skali, H.H. Parving, P.S. Parfrey Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) experience Circulation 124 2011 2903 2908
44. F.M. Clement, S. Klarenbach, M. Tonelli, J.A. Johnson, B.J. Manns The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis Arch Intern Med 169 2009 1104 1112
45. FDA FDA Drug Safety Communication; Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis Stimulating Agents in Chronic Kidney Disease 2011 http://www.fda.gov/drugs/drugsafety/ucm259639.htm Accessed May 13, 2013
46. A. Besarab, W.K. Bolton, J.K. Browne The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590
47. A.K. Singh, L. Szczech, K.L. Tang Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098
48. A.S. Kliger, S. Fishbane, F.O. Finkelstein Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment Clin J Am Soc Nephrol 7 2012 354 357
49. M. Tonelli, S. Klarenbach, N. Wiebe, F. Shrive, B. Hemmelgarn, B. Manns Erythropoiesis stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation [Technology report number 106] 2008 Canadian Agency for Drugs and Technologies in Health Ottawa
50. B.J. Manns, M. Tonelli The new FDA labeling for ESA - implications for patients and providers Clin J Am Soc Nephrol 7 2012 348 353
51. A. Besarab Optimizing anaemia management with subcutaneous administration of epoetin Nephrol Dial Transplant 20 suppl 6 2005 vi10 vi15
52. P.A. McFarlane, M.P. Hillmer, N. Dacouris A change from subcutaneous to intravenous erythropoietin increases the cost of anemia therapy Nephron Clin Pract 107 2007 c90 c96
53. C.B. Raymond, D.M. Collins, K.N. Bernstein, D.E. Skwarchuk, L.M. Vercaigne Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration Nephron Clin Pract 102 2006 c88 c92
54. L.M. Moist, N. Muirhead, L.D. Wazny, K.L. Gallo, A.P. Heidenheim, A.A. House Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis Ann Pharmacother 40 2006 198 203
55. D.M. Hynes, K.T. Stroupe, J.W. Greer Potential cost savings of erythropoietin administration in end-stage renal disease Am J Med 112 2002 169 175
56. K. Boven, S. Stryker, J. Knight The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes Kidney Int 67 2005 2346 2353
57. L.M. Moist, R.N. Foley, B.J. Barrett Clinical practice guidelines for evidence-based use of erythropoietic-stimulating agents Kidney Int Suppl 2008 S12 S18
58. S.W. Klarenbach, L.M. Moist, R.N. Foley Clinical practice guidelines for supplemental therapies and issues Kidney Int Suppl 2008 S19 S24
59. A. Besarab, J.W. Kaiser, S. Frinak A study of parenteral iron regimens in hemodialysis patients Am J Kidney Dis 34 1999 21 28
60. K. Shalansky, J. Hanko, M. Pudek, G. Li, J. Jastrzebski Iron indices after administration of sodium ferric gluconate complex in hemodialysis patients Am J Kidney Dis 58 2011 684 685
61. T. Kapoian, N.B. O'Mara, M. Carreon Iron indices and intravenous ferumoxytol: time to steady-state Ann Pharmacother 46 2012 1308 1314
62. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease update 2000 Am J Kidney Dis 37 suppl 2001 S182 S238